Trafermin
Trafermin is a recombinant human basic fibroblast growth factor (bFGF, FGF-2) that binds to FGF receptors to stimulate fibroblast proliferation, angiogenesis, granulation tissue formation, and epithelialization, accelerating wound healing and tissue repair. It has been investigated and approved in some countries (notably Japan) for promotion of healing of bedsores, leg ulcers, and surgical wounds through topical application. Its potent pro-angiogenic and mitogenic properties on endothelial cells and fibroblasts underlie its wound-healing efficacy.
Mecanismo de acción
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Trafermin is a recombinant human basic fibroblast growth factor (bFGF, FGF-2) that binds to FGF receptors to stimulate fibroblast proliferation, angiogenesis, granulation tissue formation, and epithelialization, accelerating wound healing and tissue repair. It has been investigated and approved in some countries (notably Japan) for promotion of healing of bedsores, leg ulcers, and surgical wounds through topical application. Its potent pro-angiogenic and mitogenic properties on endothelial cells and fibroblasts underlie its wound-healing efficacy.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Trafermin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108081. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trafermin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trafermin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trafermin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trafermin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trafermin"></drugfyi-drug>